ArticleEmergency medicine Australasia : EMA2026
A Retrospective Descriptive Analysis of Consultations Provided by the National Poisons Centre Relating to Medicines on the Aotearoa New Zealand Antidote Stocking Guideline, 2020-2025.
Article in Emergency medicine Australasia : EMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMany antidotes are relatively rare-use, indication-specific medicines with a variable evidence base. In Aotearoa New Zealand, there are no national statistics available on their use. This study aimed to characterize the numbers of cases and advice provided by the Aotearoa New Zealand National Poisons Centre (NZNPC) on the use of true antidotes and antidote-adjacent medicines to treat poisonings from 2020 to 2025.
methodsThe numbers of NZNPC medical/clinical toxicologist consultations advising on the use of antidotes and antidote-adjacent medicines were determined and data categorized by health region, the caller type of healthcare provider and the numbers of cases advising for and against the use of specific medicines.
resultsConsultations occurred in 2952 exposure incidents with hospital-based clinicians comprising 2800 (95%); covered all regions; and consisted of advising on use of individual antidotes/adjacent medicines 3408 times. N-acetylcysteine (1371; 40%) and charcoal (775; 23%) were most frequently discussed. Of relatively high-cost antidotes, NZNPC advised against use of fomepizole in 22/58 (38%) and digoxin-binding antibody in 36/74 (49%) cases. Of labour-intensive interventions, NZNPC advised against use of high-dose insulin euglycemic therapy in 52/89 (58%) and whole bowel irrigation in 68/135 (50%) cases.
conclusionsThere was use of the NZNPC consultation service across all regions, and the recommendations provided for each antidote ranged from mostly in favour of use to mostly against use based on the patient presentation. Utilizing a specialist medical/clinical toxicologist consultation service may assist in rationalizing care and optimizing use of healthcare resources.
Indexed as
Identifiers
42851077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.